ArticleeLife2018
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Open access · goldAbstract read
In one paragraph
Article in eLife, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 164 citations in OpenAlex.
- Cystathionine beta-synthase promotes anoikis resistance and transcoelomic metastasis in ovarian cancer via SP1- ITGB1 regulation.Experimental hematology & oncology · 2026Article
- Genome-Wide CRISPR/Cas9 Screening Identifies Modulators of THZ1 Response in Acute Myeloid Leukemia.Biomedicines · 2026Article
- Transcriptional Profile Change of NK-92 Cells in Presence of Cytokines, TGFβ Signaling Pathway Inhibitor and CDK7/12/13 Kinase Inhibitor.International journal of molecular sciences · 2026Article
- The Emerging Role of Transcription-Associated Cyclin-Dependent Kinases in Gastrointestinal Tumors.Cancers · 2026Review
- An Integrative Drug-Induced Transcriptomic Analysis Identifies Novel MYC Antagonists and Potential Synergistic Drug Combinations.Molecular carcinogenesis · 2025Article
- Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types.Cancer research communications · 2025Article
- The novel role of DUSP4 in suppressing ferroptosis and promoting cytotoxicity of CD8British journal of cancer · 2025Article
- Pan-cancer Myc modulator that targets Myc-α-tubulin interaction to drive selective mitotic catastrophe.Scientific reports · 2025Article
- Recent advances in development of CDK7 inhibitors and their clinical trials: a narrative review.Translational cancer research · 2025Review
- Dual Modes of Gene Regulation by CDK12.bioRxiv : the preprint server for biology · 2025Article
- New insights into the dule roles CDK12 in human cancers: Mechanisms and interventions for cancer therapy.Journal of pharmaceutical analysis · 2025Review
- Ovarian Cancer: Multi-Omics Data Integration.International journal of molecular sciences · 2025Review
- Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC.iScience · 2025Article
- Screening a living biobank identifies cabazitaxel as a strategy to combat acquired taxol resistance in high-grade serous ovarian cancer.Cell reports. Medicine · 2025Article
- Targeting CDK7 Enhances the Antitumor Efficacy of Enzalutamide in Androgen Receptor-Positive Triple-Negative Breast Cancer by Inhibiting c-MYC-mediated Tumorigenesis.Molecular cancer therapeutics · 2025Article
- Mechanistic Roles of Transcriptional Cyclin-Dependent Kinases in Oncogenesis: Implications for Cancer Therapy.Cancers · 2025Review
- MORE interpretable multi-omic regulatory networks to characterise phenotypes.Briefings in bioinformatics · 2025Article
- MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer.Cancer research communications · 2025Article
- Cyclin-dependent protein kinases and cell cycle regulation in biology and disease.Signal transduction and targeted therapy · 2025Review
- Reversible downregulation of MYC in a spheroid model of metastatic epithelial ovarian cancer.Cancer gene therapy · 2025Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 1 country.
Mei ZengDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.ORCID http://orcid.org/0000-0001-5316-3522
Nicholas P KwiatkowskiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
Tinghu ZhangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
Behnam NabetDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.ORCID https://orcid.org/0000-0002-6738-4200
Mousheng XuDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
Yanke LiangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
Chunshan QuanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
Jinhua WangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
Mingfeng HaoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
Sangeetha PalakurthiBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, United States.
Shan ZhouBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, United States.
Qing ZengBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, United States.
Paul T KirschmeierBelfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, United States.
Khyati MeghaniDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, United States.
Alan L LeggettDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
Jun QiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.
Geoffrey I ShapiroEarly Drug Development Center, Dana-Farber Cancer Institute, Boston, United States.
Joyce F LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.
Ursula A MatulonisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.
Charles Y LinDepartment of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, United States.ORCID https://orcid.org/0000-0002-9155-090X
Panagiotis A KonstantinopoulosDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, United States.
Nathanael S GrayDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States.ORCID http://orcid.org/0000-0001-5354-7403
Harvard University · USDana-Farber Cancer Institute · USBaylor College of Medicine · US
Funding
Transcriptional CDKs as therapeutic targets in MYC-dependent cancersR01CA197336 · NCI · DANA-FARBER CANCER INST · PI GEORGE, RANI E. · 2016 to 2020
$2.0MIdentifying and Targeting Onocgenic MYC Enhancer Control in Pediatric TumorsR01CA215452 · NCI · BAYLOR COLLEGE OF MEDICINE · PI WESTBROOK, THOMAS · 2017 to 2021
$2.0MDevelopment and Application of Selective Covalent Cdk7 InhibitorsR01CA179483 · NCI · DANA-FARBER CANCER INST · PI GRAY, NATHANAEL SCHIANDER, MITSIADES, CONSTANTINE S. · 2014 to 2016
$1.5MNCI NIH HHS NIH R01 CA179483-02NCI NIH HHS NIH R01 CA197336-02NCI NIH HHS R01 CA179483NCI NIH HHS R01 CA197336NCI NIH HHS R01 CA215452NCI NIH HHS R01CA215452-01
Abstract
High-grade serous ovarian cancer is characterized by extensive copy number alterations, among which the amplification of
Indexed as
AnimalsAntineoplastic AgentsCDC2 Protein KinaseCell Line, TumorCyclin-Dependent Kinase-Activating KinaseCyclin-Dependent KinasesDisease Models, AnimalDown-RegulationEnzyme InhibitorsFemaleHeterograftsHumansMice, SCIDNeoplasm TransplantationOvarian NeoplasmsPhenylenediaminesAntineoplastic AgentsCDC2 Protein KinaseCDK12 protein, humanCDK13 protein, humanCyclin-Dependent Kinase-Activating KinaseCyclin-Dependent KinasesEnzyme InhibitorsMYC protein, humanPhenylenediaminesProto-Oncogene Proteins c-mycPyrimidinesTHZ1 compoundcancer biologyCDK12/13CDK7humanMCL-1mouseMYCovarian cancerTHZ1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.